Back to Search
BRADLEY WOODMAN, MD
MD
Internal Medicine Physician
NPI: 1588045975IndividualAccepts Medicare
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
D87034(MD)
CMS Specialties
PrimaryINTERNAL MEDICINE
Education
UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE
Class of 2015
Research & Publications (20)
Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease.
PMID 19484127·PLoS One·2009
7-preclinical
A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for huntington disease.
PMID 19043139·Mol Cell Proteomics·2009
7-preclinical
Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease.
PMID 17986219·J Neurochem·2008
7-preclinical
Increased metabolism in the R6/2 mouse model of Huntington's disease.
PMID 17920283·Neurobiol Dis·2008
7-preclinical
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease.
PMID 18625748·J Exp Med·2008
7-preclinical
Global changes to the ubiquitin system in Huntington's disease.
PMID 17687326·Nature·2007
7-preclinical
Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.
PMID 17360721·Hum Mol Genet·2007
7-preclinical
Restriction of endogenous T cell antigen receptor beta rearrangements to Vbeta14 through selective recombination signal sequence modifications.
PMID 17360467·Proc Natl Acad Sci U S A·2007
7-preclinical
The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes.
PMID 17352931·Brain Res Bull·2007
7-preclinical
Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease.
PMID 16111888·Neurobiol Dis·2006
7-preclinical
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice.
PMID 16697652·Neurobiol Dis·2006
7-preclinical
Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease.
PMID 16651003·Neurobiol Dis·2006
7-preclinical
Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS 1H NMR spectroscopy.
PMID 16512662·J Proteome Res·2006
7-preclinical
Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target.
PMID 16311253·Hum Mol Genet·2006
4-observational
Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease.
PMID 16190907·Eur J Neurosci·2005
7-preclinical
Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease.
PMID 16183657·Hum Mol Genet·2005
7-preclinical
Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease.
PMID 16251441·J Neurosci·2005
4-observational
Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach.
PMID 15115766·Hum Mol Genet·2004
7-preclinical
Standardization and statistical approaches to therapeutic trials in the R6/2 mouse.
PMID 13679245·Brain Res Bull·2003
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2435 W. BELVEDERE AVENUE, HOFFBERGER BUILDING, SUITE 56
BALTIMORE, MD 21215 - Phone
- (410) 601-0594
Quick Facts
- NPI
- 1588045975
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 11
- Publications
- 20
Are you this provider?
Claim Your Profile